Laurence Katznelson, MD
Endocrinology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Cedars-Sinai Medical Center · 788 clinicians in this group
Hospitals listed: Cedars-Sinai Medical Center. That is not proof they admit you there this week.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Katznelson’s office at (310) 423-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G87279 · Current
Licensed to practise in California · since 2004 · expires 2027-12-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Cedars-Sinai Medical CenterLos Angeles, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Cedars Sinai Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Postoperative sepsis rate: 7.77 (6.11 to 9.44) · 6,132 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.2 to 14.7) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 134.15 (109.33 to 158.98) · 557 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.386, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.661, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.628, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.503, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.8 (3 to 4.8) · 1,174 cases, Jan 2024 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.8) · 2,580 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Cedars-Sinai Medical Center
Behind the star rating — Deaths: 7 better, 1 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 7.77 (6.11 to 9.44) · 6,132 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.2 to 14.7) · 1,174 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.15 (109.33 to 158.98) · 557 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.386 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.661 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.628 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.503 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.8 (3 to 4.8) · 1,174 cases | Better | Jan 2024 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.8) · 2,580 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.66 (0.06 to 1.25) · 8,257 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.92 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 223 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.9 · 191 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 8.3 · 409 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.5 · 1,544 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.5 · 1,742 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 549 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.3 · 9,504 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.28) · 29,170 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.05 to 0.32) · 31,661 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.1 (3.06 to 5.14) · 11,199 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0.47 to 2.29) · 6,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (1.24 to 2.86) · 10,075 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.2 (5.76 to 10.65) · 6,012 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.91 (0.72 to 3.11) · 2,803 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.75 (0.47 to 1.03) · 27,865 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 472 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.437 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.168 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 492 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 1,750 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.9 · 498 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5.8 · 1,908 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.7 · 1,850 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 1,572 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.7 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 172 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 240 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.1 to 17.5) · 1,197 cases | No different | Jan 2022 – Dec 2024 |
What patients said (1,081 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$3,525
Medicare paid this office $3,525 for 43 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 26 | $2,538 | $98 |
| Return visit (30+ min) | 15 | $646 | $43 |
Who their Medicare patients are
43 Original Medicare patients in 2024. Average age 69 · Women 44% · Health risk score 1.20. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 51% · Coronary heart disease 30%.
The office billed $23,606, Medicare allowed $6,309 and paid $3,525; for 45 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 43 | 45 | 69 | 1.20 | $23,606 | $3,525 |
| 2023 | 133 | 172 | 71 | 1.34 | $85,598 | $15,116 |
| 2022 | 122 | 171 | 70 | 1.22 | $86,573 | $13,551 |
| 2021 | 139 | 203 | 68 | 1.47 | $110,773 | $16,089 |
| 2020 | 121 | 171 | 68 | 1.43 | $84,259 | $11,619 |
| 2019 | 127 | 176 | 69 | 1.61 | $29,535 | $12,137 |
| 2018 | 131 | 193 | 68 | 1.78 | $31,321 | $11,763 |
| 2017 | 138 | 215 | 66 | 1.50 | $37,928 | $13,436 |
| 2016 | 144 | 283 | 70 | 1.75 | $73,328 | $20,794 |
| 2015 | 126 | 225 | 70 | 1.38 | $48,566 | $14,692 |
| 2014 | 115 | 206 | 65 | 1.23 | $40,675 | $11,758 |
| 2013 | 102 | 207 | 66 | 1.34 | $46,812 | $14,362 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 109 | $10,649 | $79 |
| New patient visit (45+ min) | 26 | $3,069 | $118 |
2022: 2 services
| Return visit (30+ min) | 106 | $10,974 | $76 |
| New patient visit (45+ min) | 13 | $1,368 | $105 |
2021: 2 services
| Return visit (30+ min) | 113 | $11,885 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,328 | $66 |
2020: 3 services
| Return visit (30+ min) | 95 | $7,614 | $64 |
| New patient visit (45+ min) | 13 | $1,386 | $107 |
| Return visit (30+ min) | 14 | $1,030 | $74 |
2019: 3 services
| Return visit (30+ min) | 37 | $2,966 | $69 |
| Short return visit (20+ min) | 62 | $2,508 | $39 |
| New patient visit (45+ min) | 13 | $1,399 | $108 |
2018: 4 services
| Short return visit (20+ min) | 71 | $3,474 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,779 | $81 |
| Return visit (30+ min) | 17 | $1,272 | $64 |
| Short return visit (20+ min) | 20 | $715 | $34 |
2017: 3 services
| Short return visit (20+ min) | 71 | $3,332 | $39 |
| Short return visit (20+ min) | 29 | $1,799 | $45 |
| New patient visit (45+ min) | 11 | $1,099 | $100 |
2016: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $4,528 | $89 |
| Short return visit (20+ min) | 61 | $3,390 | $43 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,632 | $164 |
| New patient visit (45+ min) | 19 | $1,730 | $91 |
| New patient visit (45+ min) | 12 | $1,458 | $121 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,167 | $97 |
| Return visit (30+ min) | 22 | $1,020 | $46 |
| Short return visit (20+ min) | 17 | $889 | $44 |
2015: 4 services
| Short return visit (20+ min) | 63 | $2,941 | $38 |
| Return visit (30+ min) | 33 | $2,780 | $68 |
| New patient visit (45+ min) | 23 | $2,657 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,745 | $65 |
2014: 4 services
| Return visit (30+ min) | 53 | $3,077 | $50 |
| Short return visit (20+ min) | 61 | $2,931 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,601 | $64 |
| New patient visit (30+ min) | 23 | $1,418 | $62 |
2013: 2 services
| Return visit (30+ min) | 70 | $6,054 | $65 |
| New patient visit (30+ min) | 21 | $1,385 | $66 |
Medicaid work
$494 in 2022
Medicaid paid $494 for 16 billed services this clinician did in 2022, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 16 | $494 |
| 2022 | 16 | 1 | 16 | $494 |
| 2020 | 12 | 1 | 12 | $435 |
See the largest Medicaid services in earlier years
2020
| Return visit (30+ min) | 12 | $435 |
Drugs they prescribed that Part D paid
$745
Pharmacies billed $745 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 38) in 2024. Too few prescriptions to compare fairly with other clinicians.
26 generic and 12 brand-name prescriptions · $745 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydrocortisone | 14 | $161 | $11 |
| Levothyroxine | 12 | $67 | $6 |
Year by year
| 2024 | 38 | None | 0% (0) | 32% | $745 |
| 2023 | 40 | 21 | 0% (0) | 53% | $897 |
| 2022 | 63 | 20 | 0% (0) | 32% | $11,079 |
| 2021 | 68 | 21 | 0% (0) | 50% | $1,923 |
| 2020 | 93 | 27 | 0% (0) | 58% | $25,434 |
| 2019 | 87 | 28 | 0% (0) | 49% | $12,016 |
| 2018 | 102 | 35 | None | 47% | $66,017 |
| 2017 | 84 | 21 | None | None | $22,460 |
| 2016 | 75 | 27 | None | None | $38,302 |
| 2015 | 120 | 26 | None | 65% | $51,230 |
| 2014 | 130 | 29 | 0% (0) | 64% | $84,153 |
| 2013 | 151 | 34 | 0% (0) | 55% | $91,712 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Levothyroxine | 27 | $417 | $15 |
2022: 2 drugs
| Desmopressin Acetate | 13 | $1,788 | $138 |
| Levothyroxine | 20 | $322 | $16 |
2021: 2 drugs
| Hydrocortisone | 21 | $621 | $30 |
| Levothyroxine | 34 | $523 | $15 |
2020: 2 drugs
| Levothyroxine | 60 | $1,111 | $19 |
| Hydrocortisone | 24 | $485 | $20 |
2019: 1 drug
| Levothyroxine | 44 | $957 | $22 |
2018: 2 drugs
| Hydrocortisone | 14 | $821 | $59 |
| Levothyroxine | 30 | $727 | $24 |
2017: 2 drugs
| Hydrocortisone | 23 | $758 | $33 |
| Levothyroxine | 25 | $543 | $22 |
2016: 1 drug
| Levothyroxine | 11 | $244 | $22 |
2015: 3 drugs
| Androgel | 30 | $22,155 | $739 |
| Omnitrope | 11 | $5,038 | $458 |
| Hydrocortisone | 13 | $1,323 | $102 |
2014: 5 drugs
| Norditropin Flexpro | 13 | $18,010 | $1,385 |
| Humatrope | 26 | $17,892 | $688 |
| Androgel | 16 | $9,053 | $566 |
| Omnitrope | 11 | $4,503 | $409 |
| Hydrocortisone | 18 | $552 | $31 |
2013: 6 drugs
| Somatuline Depot | 12 | $39,082 | $3,257 |
| Norditropin Flexpro | 18 | $17,543 | $975 |
| Humatrope | 19 | $12,540 | $660 |
| Androgel | 15 | $9,446 | $630 |
| Hydrocortisone | 25 | $845 | $34 |
| Levothyroxine | 12 | $141 | $12 |
Money from drug and device companies
$4,836 in 2025
| 2025 | 4 | 4 | $4,765 | $4,836 |
| 2024 | 2 | 4 | $28,962 | $29,301 |
| 2023 | 2 | 7 | $13,481 | $14,636 |
| 2022 | 2 | 2 | $1,275 | $1,302 |
| 2021 | 6 | 8 | $21,590 | $21,590 |
| 2020 | 5 | 9 | $11,435 | $11,591 |
| 2019 | 2 | 20 | $13,073 | $15,968 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ascendis Pharma Endocrinology | None | $4,315 | 1 payment
|
| Alexion Pharmaceuticals | None | $450 | 1 payment
|
| Corcept Therapeutics | Korlym | $37 | 1 payment
|
| Chiesi USA | Mycapssa | $34 | 1 payment
|
See all 4 published payments
| Ascendis Pharma Endocrinology | Consulting · 2025-11-27 | None | $4,315 |
| Chiesi USA | Meals · 2025-07-12 | Mycapssa | $34 |
| Alexion Pharmaceuticals | Consulting · 2025-07-09 | None | $450 |
| Corcept Therapeutics | Meals · 2025-07-09 | Korlym | $37 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $29,301
| Corcept Therapeutics | Korlym | $26,162 | 2 payments
|
| Alexion Pharmaceuticals | None | $3,139 | 2 payments
|
2023: $14,636
| Novo Nordisk | Norditropin | $9,124 | 6 payments
|
| Corcept Therapeutics | Korlym | $5,513 | 1 payment
|
2022: $1,302
| Corcept Therapeutics | Korlym | $1,275 | 1 payment
|
| Novo Nordisk | None | $27 | 1 payment
|
2021: $21,590
| Recordati Rare Diseases Inc. | None | $5,875 | 2 payments
|
| Xeris Pharmaceuticals | None | $4,900 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $3,440 | 2 payments
|
| Ipsen Innovation | None | $3,010 | 1 payment
|
| Ipsen Biopharm | Somatuline Depot | $2,365 | 1 payment
|
| Hra Pharma Rare Diseases | Metopirone | $2,000 | 1 payment
|
2020: $11,591
| Corcept Therapeutics | Korlym | $3,515 | 2 payments
|
| Recordati Rare Diseases Inc. | None | $3,025 | 1 payment
|
| Novo Nordisk | Norditropin | $2,876 | 4 payments
|
| Strongbridge US | None | $1,800 | 1 payment
|
| Mallinckrodt | None | $375 | 1 payment
|
2019: $15,968
| Novo Nordisk | Norditropin | $15,849 | 17 payments
|
| Corcept Therapeutics | Korlym | $119 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Ascendis Pharma Inc · Foresight · 2023 | Their institution | $55,782 |
| Ascendis Pharma, Inc. · Foresight · 2022 | Their institution | $19,294 |
| Novartis Pharmaceuticals Corporation · An Open Label Multicenter Single Arm Study of Pasireotide Lar in Patients With Rare Tumors of Neuroendocrine Origin · 2019 | Their institution | $6,403 |
| Novartis Pharmaceuticals Corporation · An Open Label Multi Center Pasireotide Rollover Protocol for Patients Who Have Completed A Previous Novartis Sponsored Pasireotide Study and Are Judged By the Investigator To Benefit From Continued Pasireotide Treatment · 2019 | Their institution | $3,954 |
| Ascendis Pharma Inc · Foresight · 2024 | Their institution | $3,520 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013082643
- Licence
- CA G87279California G87279: Current · expires 2027-12-31
- Trained
- University of California, Geffen School of Medicine, 1985
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 4140 W 190th St, Torrance, CA, 90504
- NPI first listed
- 2006-11-21
- NPI last updated
- 2024-05-07
- NPI record certified
- 2024-05-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305 · 875 Blake Wilbur Dr, Stanford, CA, 94035